News Center
-91.jpg)
All
2025
2024
2023
2022
2021
2020
-
LaNova Medicines and Turning Point Therapeutics Enter Into a Licensing Agreement for LM-3022022-05-05
Learn More
-
LaNova Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022LaNova Medicines will present two posters featuring preclinical data of LM-108 and LM-305 (Abstract No. 6008 & 6020) at the American Association for Cancer Research (AACR) 2022 Annual Meeting, to be held April 8-13, 2022.
2022-03-31Learn More
-
LM-108 Submitted US FDA Clinical Trial Application
CCR8 antibody LM-108 submitted US FDA clinical study application in December 2021. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-108.
2021-12-23Learn More
-
LaNova Medicines Launches R&D Center after Relocation2021-11-30
Learn More
-
LaNova Medicines and Junshi Biosciences Enter into Multiple Combo Clinical Collaborations2021-10-23
Learn More
-
LaNova Medicines and CBMG Enter into A Strategic Partnership2021-10-22Learn More